Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

SIMPATHIC Accelerating drug repurposing for rare neurological, neurometabolic and neuromuscular disorders by exploiting SIMilarities in clinical and molecular PATHology

Coordinator
Stichting Radboud Universitair Medisch Centrum, Netherlands
Runs
1 July 2023 to 30 June 2028
Status
Running
EU funding
€8.8m
Total cost
€8.8m
Partners
21 organisations in 10 countries
Type
Research and Innovation Action
Grant agreement
101080249

What the project is doing

In the project's own words, from its summary on CORDIS.

Drug repurposing can fill an important gap for rare disease patient groups with large unmet medical needs. In comparison to traditional drug development, drug repurposing reduces the time and costs for drug development, regulatory approval, and market authorization. Yet, we need to increase the efficiency of the drug repurposing pathway to provide broader access to new therapeutic modalities for larger groups of patients.

SIMPATHIC’s main objective is to accelerate drug repurposing for rare neurological, neurometabolic and neuromuscular disorders. SIMPATHIC’s main accelerating innovation is the simultaneous drug development for groups of patients with different genetic diagnoses but overlapping neurological symptoms and molecular pathomechanisms. SIMPATHIC’s key outputs accelerating the drug repurposing pathway include: Standard operating procedures for culturing stem cell-derived neuronal cell models with proven relevance for clinical symptoms and amenable to high-throughput drug screens; New drug repurposing candidates with proven efficacy in advanced brain-on-a-chip and 3D brain organoid models, as demonstrated by reversal of molecular biomarker signatures and cellular readouts associated with clinical symptoms; Designs of innovative basket clinical trials to which patients with different disorders are recruited, utilizing and aggregating personalized clinical endpoints; A training module for patients and patient organizations to empower them as drivers of the drug repurposing pathway; Blueprints for intellectual property strategies, business models, regulatory dossiers and patient access strategies, developed in co-creation between all relevant stakeholders.

SIMPATHIC’s proof-of-concept for the simultaneous development of repurposed drugs for multiple indications will show the path forward to development of personalized treatment opportunities for groups of rare disease patients in a cost- and time-efficient manner.

Topics

Who is involved

OrganisationCityCountryRole
Stichting Radboud Universitair Medisch CentrumNijmegenNetherlandsCoordinator
Children's Hospital of Eastern Ontario Research Institute IncOttawaCanadaParticipant
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Eberhard Karls Universitaet TuebingenTuebingenGermanyParticipant
Heinrich-Heine-Universitaet DuesseldorfDusseldorfGermanyParticipant
Universitatsklinikum HeidelbergHeidelbergGermanyParticipant
A. Persidis & Sia OeAthinaGreeceParticipant
Elpen Pharmaceutical Co IncPikermiGreeceAssociatedpartner
National Center for Scientific Research ""demokritos""""Agia ParaskeviGreeceParticipant
Fair Data Systems SLMadridSpainParticipant
ApteeusLilleFranceParticipant
Euro-DymaParisFranceParticipant
Fondation Maladies RaresParisFranceParticipant
Universite Du LuxembourgEsch-Sur-AlzetteLuxembourgParticipant
Eatris EricAmsterdamNetherlandsParticipant
International Mito PatientsBaarnNetherlandsParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
Stichting Eupati FoundationUtrechtNetherlandsParticipant
Faculdade de Farmácia da Universidade de LisboaLisboaPortugalParticipant
Univerza V LjubljaniLjubljanaSloveniaParticipant
Euro-AtaxiaLondonUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI